Literature DB >> 26568413

Cancer cell-selective killing polymer/copper combination.

Huacheng He1, Diego Altomare1, Ufuk Ozer2, Hanwen Xu1, Kim Creek1, Hexin Chen2, Peisheng Xu1.   

Abstract

Chemotherapy has been adopted for cancer treatment for decades. However, its efficacy and safety are frequently compromised by the multidrug-resistance of cancer cells and the poor cancer cell selectivity of anticancer drugs. Hereby, we report a combination of a pyridine-2-thiol containing polymer and copper which can effectively kill a wide spectrum of cancer cells, including drug resistant cancer cells, while sparing normal cells. The polymer nanoparticle enters cells via an exofacial thiol facilitated route, and releases active pyridine-2-thiol with the help of intracellularly elevated glutathione (GSH). Due to their high GSH level, cancer cells are more vulnerable to the polymer/copper combination. In addition, RNA microarray analysis revealed that the treatment can reverse cancer cells' upregulated oncogenes (CIRBP and STMN1) and downregulated tumor suppressor genes (CDKN1C and GADD45B) to further enhance the selectivity for cancer cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26568413      PMCID: PMC4679545          DOI: 10.1039/c5bm00325c

Source DB:  PubMed          Journal:  Biomater Sci        ISSN: 2047-4830            Impact factor:   6.843


  32 in total

1.  Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.

Authors:  F Wang; P Jiao; M Qi; M Frezza; Q P Dou; B Yan
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

2.  Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors.

Authors:  Daishun Ling; Wooram Park; Sin-Jung Park; Yang Lu; Kyoung Sub Kim; Michael J Hackett; Byung Hyo Kim; Hyeona Yim; Yong Sun Jeon; Kun Na; Taeghwan Hyeon
Journal:  J Am Chem Soc       Date:  2014-04-01       Impact factor: 15.419

Review 3.  Advances in copper complexes as anticancer agents.

Authors:  Carlo Santini; Maura Pellei; Valentina Gandin; Marina Porchia; Francesco Tisato; Cristina Marzano
Journal:  Chem Rev       Date:  2013-10-08       Impact factor: 60.622

Review 4.  p57(Kip2) and cancer: time for a critical appraisal.

Authors:  Adriana Borriello; Ilaria Caldarelli; Debora Bencivenga; Maria Criscuolo; Valeria Cucciolla; Annunziata Tramontano; Adriana Oliva; Silverio Perrotta; Fulvio Della Ragione
Journal:  Mol Cancer Res       Date:  2011-08-04       Impact factor: 5.852

5.  Multicompartment intracellular self-expanding nanogel for targeted delivery of drug cocktail.

Authors:  Remant Bahadur K C; Peisheng Xu
Journal:  Adv Mater       Date:  2012-09-24       Impact factor: 30.849

Review 6.  A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments.

Authors:  Kenta Masui; Beatrice Gini; Jill Wykosky; Ciro Zanca; Paul S Mischel; Frank B Furnari; Webster K Cavenee
Journal:  Carcinogenesis       Date:  2013-03-01       Impact factor: 4.944

Review 7.  The hallmarks of CDKN1C (p57, KIP2) in cancer.

Authors:  Edel Kavanagh; Bertrand Joseph
Journal:  Biochim Biophys Acta       Date:  2011-04-03

8.  On the interaction of copper(II) with disulfiram.

Authors:  David J Lewis; Parikshit Deshmukh; Aleksander A Tedstone; Floriana Tuna; Paul O'Brien
Journal:  Chem Commun (Camb)       Date:  2014-09-18       Impact factor: 6.222

9.  Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.

Authors:  M T Schweizer; J Lin; A Blackford; A Bardia; S King; A J Armstrong; M A Rudek; S Yegnasubramanian; M A Carducci
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-08-20       Impact factor: 5.554

10.  STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells.

Authors:  Javed Akhtar; Zhou Wang; Che Yu; Chen-Sheng Li; Yu-Long Shi; Hong-Jun Liu
Journal:  BMC Cancer       Date:  2014-01-16       Impact factor: 4.430

View more
  7 in total

1.  Redox Potential-Sensitive N-Acetyl Cysteine-Prodrug Nanoparticles Inhibit the Activation of Microglia and Improve Neuronal Survival.

Authors:  Eleni Markoutsa; Peisheng Xu
Journal:  Mol Pharm       Date:  2017-04-04       Impact factor: 4.939

2.  Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly.

Authors:  Huacheng He; Eleni Markoutsa; Jing Li; Peisheng Xu
Journal:  Acta Biomater       Date:  2017-12-30       Impact factor: 8.947

3.  A bioactivatable self-quenched nanogel for targeted photodynamic therapy.

Authors:  Huacheng He; Anna-Liisa Nieminen; Peisheng Xu
Journal:  Biomater Sci       Date:  2019-10-02       Impact factor: 6.843

Review 4.  Recent progress in the research of cold-inducible RNA-binding protein.

Authors:  Peng Zhong; He Huang
Journal:  Future Sci OA       Date:  2017-10-04

Review 5.  Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy.

Authors:  Seong-Bin Yang; Nipa Banik; Bomin Han; Dong-Nyeong Lee; Jooho Park
Journal:  Pharmaceutics       Date:  2022-06-29       Impact factor: 6.525

Review 6.  Cold-inducible proteins CIRP and RBM3, a unique couple with activities far beyond the cold.

Authors:  Xinzhou Zhu; Christoph Bührer; Sven Wellmann
Journal:  Cell Mol Life Sci       Date:  2016-05-04       Impact factor: 9.261

7.  Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related Aβ42 Oligomers and Protect Synapses.

Authors:  Songlin Li; Eric Y Hayden; Veronica J Garcia; Dieu-Trang Fuchs; Julia Sheyn; David A Daley; Altan Rentsendorj; Tania Torbati; Keith L Black; Ueli Rutishauser; David B Teplow; Yosef Koronyo; Maya Koronyo-Hamaoui
Journal:  Front Immunol       Date:  2020-01-31       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.